Stocks›Healthcare›BMY

BMY

Bristol-Myers Squibb Company

NYSEResearch view

Bristol-Myers Squibb Company operates in the Pharmaceutical Preparations industry.

$59.59+1.33%

Oct 6 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsLarge-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around late October, going by its own filing history. The company has not announced a date yet. Its matching report came Oct 30, 2025 and Oct 31, 2024, during the session.

Last report

Jul 30, 2026+2.79%

during the session

Last 4, next close

median 4.25% either way

up 4 of 4

Every report since 2022 →Earnings calendar →

DateEventSourceNext close

Aug 19Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple MyelomaPR NewswirePR Newswire+2.36%
Jul 30Earnings release, during the session · 8-KSEC EDGARSEC EDGAR ↗+2.79%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

What happened · big days

26 big days in a year, and what we hold on each

A big day is a close more than 2.86% from the one before, three times BMY’s median day (0.95%). On 9 of the 26, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±2.86%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayBMYWhat we hold that dayGroup (median of 4) · each

1 Oct 30, 2025+7.09%
Resultsgroup +1.3%, did not move with it
1Oct 30, 2025+7.09%
ResultsFirst close after the Oct 30 results filing
+1.3% did not move with itLLY +3.8 · ABBV +1.4 · JNJ +1.3 · MRK −0.3
2 Nov 11, 2025+3.09%
Before our storiesgroup +2.9%, moved with BMY
2Nov 11, 2025+3.09%
Before our stories
+2.9% moved with BMYMRK +4.8 · ABBV +3.0 · JNJ +2.9 · LLY +2.3
3 Nov 14, 2025−4.07%
Before our storiesgroup +0.1%, did not move with it
3Nov 14, 2025−4.07%
Before our stories
+0.1% did not move with itMRK −0.0 · ABBV +0.0 · LLY +0.2 · JNJ +0.3
4 Nov 24, 2025+3.26%
Before our storiesgroup +1.0%, did not move with it
4Nov 24, 2025+3.26%
Before our stories
+1.0% did not move with itMRK +2.7 · JNJ +1.1 · LLY +1.0 · ABBV −2.9
5 Dec 3, 2025+5.62%
Before our storiesgroup +0.6%, did not move with it
5Dec 3, 2025+5.62%
Before our stories
+0.6% did not move with itABBV +2.6 · MRK +1.2 · JNJ −0.0 · LLY −1.2
6 Dec 15, 2025+3.59%
Before our storiesgroup +1.5%, did not move with it
6Dec 15, 2025+3.59%
Before our stories
+1.5% did not move with itLLY +3.4 · ABBV +1.9 · JNJ +1.2 · MRK −0.0
7 Jan 7, 2026+4.23%
Before our storiesgroup +2.7%, moved with BMY
7Jan 7, 2026+4.23%
Before our stories
+2.7% moved with BMYABBV +4.2 · LLY +4.1 · JNJ +1.3 · MRK −0.3
8 Feb 4, 2026+2.91%
Before our storiesgroup +1.4%, did not move with it
8Feb 4, 2026+2.91%
Before our stories
+1.4% did not move with itLLY +10.3 · MRK +2.1 · JNJ +0.6 · ABBV −3.8
9 Feb 5, 2026+3.30%
Resultsgroup +1.0%, did not move with it
9Feb 5, 2026+3.30%
ResultsFirst close after the Feb 5 results filing
+1.0% did not move with itJNJ +1.4 · MRK +1.2 · ABBV +0.9 · LLY −7.8
10 Feb 6, 2026+4.15%
Before our storiesgroup +1.9%, did not move with it
10Feb 6, 2026+4.15%
Before our stories
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.8 · JNJ +0.9
11 Apr 2, 2026−3.45%
Before our storiesgroup −1.2%, did not move with it
11Apr 2, 2026−3.45%
Before our stories
−1.2% did not move with itABBV −2.9 · LLY −2.0 · JNJ −0.4 · MRK +0.0
12 Apr 30, 2026+5.21%
Resultsgroup +2.4%, did not move with it
12Apr 30, 2026+5.21%
ResultsFirst close after the Apr 30 results filing
+2.4% did not move with itLLY +9.8 · ABBV +3.6 · JNJ +1.1 · MRK −1.6
13 May 1, 2026−3.91%
Before our storiesgroup +0.8%, did not move with it
13May 1, 2026−3.91%
Before our stories
+0.8% did not move with itABBV −2.2 · JNJ −1.2 · MRK +2.7 · LLY +3.1
14 Jun 1, 2026−3.90%
Before our storiesgroup −2.1%, moved with BMY
14Jun 1, 2026−3.90%
Before our stories
−2.1% moved with BMYMRK −3.0 · ABBV −2.2 · LLY −2.1 · JNJ −0.8
15 Jun 4, 2026+3.44%
Before our storiesgroup +4.0%, moved with BMY
15Jun 4, 2026+3.44%
Before our stories
+4.0% moved with BMYMRK +4.8 · LLY +4.3 · ABBV +3.6 · JNJ +2.2
16 Jun 8, 2026−2.97%
Before our storiesgroup −0.7%, did not move with it
16Jun 8, 2026−2.97%
Before our stories
−0.7% did not move with itABBV −1.8 · MRK −1.1 · JNJ −0.3 · LLY +1.6
17 Jun 26, 2026+3.85%
Nothing on BMYgroup +4.1%, moved with BMY
17Jun 26, 2026+3.85%
Nothing on BMYNo BMY story, brief or results filing in our record that day
+4.1% moved with BMYLLY +7.1 · ABBV +4.2 · JNJ +4.0 · MRK +2.6
18 Jul 2, 2026+2.99%
Nothing on BMYgroup +3.5%, moved with BMY
18Jul 2, 2026+2.99%
Nothing on BMYNo BMY story, brief or results filing in our record that day
+3.5% moved with BMYABBV +4.0 · JNJ +3.6 · MRK +3.3 · LLY +1.9
19 Jul 13, 2026+3.06%
Nothing on BMYgroup +0.1%, did not move with it
19Jul 13, 2026+3.06%
Nothing on BMYNo BMY story, brief or results filing in our record that day
+0.1% did not move with itMRK +0.4 · JNJ +0.3 · ABBV −0.0 · LLY −0.6
20 Jul 14, 2026−4.03%
Nothing on BMYgroup −2.0%, did not move with it
20Jul 14, 2026−4.03%
Nothing on BMYNo BMY story, brief or results filing in our record that day
−2.0% did not move with itMRK −2.6 · LLY −2.5 · JNJ −1.5 · ABBV −1.3
21 Jul 15, 2026+3.11%
Nothing on BMYgroup +0.0%, did not move with it
21Jul 15, 2026+3.11%
Nothing on BMYNo BMY story, brief or results filing in our record that day
+0.0% did not move with itMRK +2.3 · LLY +0.3 · ABBV −0.3 · JNJ −2.7
22 Jul 16, 2026+3.05%
Nothing on BMYgroup +2.2%, moved with BMY
22Jul 16, 2026+3.05%
Nothing on BMYNo BMY story, brief or results filing in our record that day
+2.2% moved with BMYABBV +4.2 · MRK +3.3 · JNJ +1.2 · LLY +1.1
23 Aug 5, 2026−3.43%
Nothing on BMYgroup +1.0%, did not move with it
23Aug 5, 2026−3.43%
Nothing on BMYNo BMY story, brief or results filing in our record that day
+1.0% did not move with itMRK +0.3 · ABBV +1.0 · JNJ +1.0 · LLY +4.9
24 Aug 20, 2026−3.17%
Nothing on BMYgroup −2.2%, moved with BMY
24Aug 20, 2026−3.17%
Nothing on BMYNo BMY story, brief or results filing in our record that day
−2.2% moved with BMYLLY −2.8 · JNJ −2.2 · MRK −2.1 · ABBV −1.6
25 Sep 8, 2026−3.19%
Nothing on BMYgroup −2.2%, moved with BMY
25Sep 8, 2026−3.19%
Nothing on BMYNo BMY story, brief or results filing in our record that day
−2.2% moved with BMYABBV −3.0 · JNJ −2.2 · LLY −2.2 · MRK −1.2
26 Oct 5, 2026−3.83%
Nothing on BMYgroup −0.6%, did not move with it
26Oct 5, 2026−3.83%
Nothing on BMYNo BMY story, brief or results filing in our record that day
−0.6% did not move with itMRK −3.3 · JNJ −1.2 · LLY +0.0 · ABBV +1.1

A story on the same day is not a cause, and a group move is not proof either. Group: the median of LLY, JNJ, ABBV and MRK that day, the largest companies in BMY’s SEC industry; “moved with BMY” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). BMY reports during the trading day, so day 1 is that day’s close. 3 of 4 times, day 6 ended on the same side as day 1.

Reported Oct 30, 2025

day 1+7.09%day 6+9.46%

Reported Feb 5, 2026

day 1+3.30%day 6+3.89%

Reported Apr 30, 2026

day 1+5.21%day 6−2.33%

Reported Jul 30, 2026

day 1+2.79%day 6+1.66%

Next report: expected late OctoberEstimated from the dates of its last four results filings. Not announced. Since the Jul 30 report: −6.80%. Four reports is a small sample.

Every report since 2022 →

Each line is BMY’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

The numbers · FY2025, filed

SEC EDGAR

Market cap$124.9B

Revenue$48.2B−0.20%

Net income$7.1B

EPS, diluted$3.46+178.50%

Return on equity38.1%

Debt / equity2.54

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$124.9B

Enterprise Value$161.8B

Income$7.1B

Sales$48.2B

Book/sh$9.06

Cash/sh$5.00

Dividend TTM$2.49

Payout72%

Employees—

IPO—

Quick Ratio1.14

Current Ratio1.26

Debt/Eq2.54

EPS (ttm)$3.46

EPS this Y178.5%

EPS past 3/5Y5.5%

Sales past 3/5Y1.4%

EPS Y/Y TTM178.5%

Sales Y/Y TTM-0.2%

Shs Outstand2.04B

ROA7.8%

ROE38.1%

ROIC—

Gross Margin—

Oper. Margin—

Profit Margin14.6%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$46.4B

FY21

$46.2B

FY22

$45.0B

FY23

$48.3B

FY24

$48.2B

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$46.4B	$46.2B	$45.0B	$48.3B	$48.2B
Gross Profit	—	—	—	—	—
Operating Income	—	—	—	—	—
Net Income	$7.0B	$6.3B	$8.0B	$-8.9B	$7.1B
Diluted EPS	$3.12	$2.95	$3.86	$-4.41	$3.46
Operating Cash Flow	$16.2B	$13.1B	$13.9B	$15.2B	$14.2B
Free Cash Flow	$15.2B	$11.9B	$12.7B	$13.9B	$12.8B

Same industry

BMY against four drug peers, a year at 100

BMY is up 33.8% in a year. Merck is up 62.3% and Eli Lilly 37.2%. Of these four, Johnson & Johnson (+32.6%) and AbbVie (+15.3%) did less. Weekly closes, Oct 10, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

BMY +33.8%. Merck +62.3%, Eli Lilly +37.2%, Johnson & Johnson +32.6%, AbbVie +15.3%. Weekly closes, Oct 10, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in BMY’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

Same industry

In the screener →

LLY$1.08T JNJ$617.0B ABBV$464.4B MRK$356.0B ABT$168.7B PFE$158.5B VRTX$127.9B REGN$79.8B

Follow the news. Track the move.

BMY story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Aug 19

FDA approves Bristol Myers Squibb's ZENBEXUS, first CELMoD therapy for multiple myeloma

Hematogenix said its multiple myeloma minimal residual disease assay measured the primary efficacy endpoint supporting FDA accelerated approval of Bristol Myers Squibb's ZENBEXUS, making the test part of the regulatory foundation for the first approved CELMoD therapy in multiple myeloma.

Since story

-11.9%

2026-08-19 → 2026-10-06

PR Newswire · 48d ago

View both sides →

Follow the news. Track the move.